GRAIL's stock fell 4.2% despite positive price targets, due to poor financials and insider sales.

GRAIL's stock price dropped 4.2% on Friday amid negative earnings reports showing poor financial metrics. Despite optimistic price target hikes by Morgan Stanley and Canaccord Genuity Group, the company's negative return on equity and net margin, coupled with significant insider stock sales, have unsettled investors. GRAIL specializes in early cancer detection using advanced technology.